Drug-Target identification in COVID-19 disease mechanisms using computational systems biology approaches

dc.contributor.authorNiarakis, Anna
dc.contributor.authorOstaszewski, Marek
dc.contributor.authorMazein, Alexander
dc.contributor.authorKuperstein, Inna
dc.contributor.authorKutmon, Martina
dc.contributor.authorGillespie, Marc E.
dc.contributor.authorFunahashi, Akira
dc.contributor.authorAichem, Michael
dc.contributor.authorKlein, Karsten
dc.contributor.authorSchreiber, Falk
dc.date.accessioned2024-01-16T11:33:16Z
dc.date.available2024-01-16T11:33:16Z
dc.date.issued2024-02-13
dc.description.abstractThe COVID-19 Disease Map project is a large-scale community effort uniting 277 scientists from 130 Institutions around the globe. We use high-quality, mechanistic content describing SARS-CoV-2-host interactions and develop interoperable bioinformatic pipelines for novel target identification and drug repurposing. Extensive community work allowed an impressive step forward in building interfaces between Systems Biology tools and platforms.Our framework can link biomolecules from omics data analysis and computational modelling to dysregulated pathways in a cell-, tissue-or patient-specific manner. Drug repurposing using text mining and AI-assisted analysis identified potential drugs, chemicals and microRNAs that could target the identified key factors. Results revealed drugs already tested for anti-COVID-19 efficacy, providing a mechanistic context for their mode of action, and drugs already in clinical trials for treating other diseases, never tested against COVID-19. The key advance is that the proposed framework is versatile and expandable, offering a significant upgrade in the arsenal for virus-host interactions and other complex pathologies.
dc.description.versionpublisheddeu
dc.identifier.doi10.3389/fimmu.2023.1282859
dc.identifier.ppn1899381287
dc.identifier.urihttps://kops.uni-konstanz.de/handle/123456789/69067
dc.language.isoeng
dc.subjectSARS-CoV-2
dc.subjectSystems Biology
dc.subjectDisease maps
dc.subjectmechanistic models
dc.subjectdynamic models
dc.subjectSystems Medicine
dc.subjectlarge-scale community effort
dc.subject.ddc004
dc.titleDrug-Target identification in COVID-19 disease mechanisms using computational systems biology approacheseng
dc.typeJOURNAL_ARTICLE
dspace.entity.typePublication
kops.citation.bibtex
@article{Niarakis2024-02-13DrugT-69067,
  year={2024},
  doi={10.3389/fimmu.2023.1282859},
  title={Drug-Target identification in COVID-19 disease mechanisms using computational systems biology approaches},
  volume={14},
  journal={Frontiers in Immunology},
  author={Niarakis, Anna and Ostaszewski, Marek and Mazein, Alexander and Kuperstein, Inna and Kutmon, Martina and Gillespie, Marc E. and Funahashi, Akira and Aichem, Michael and Klein, Karsten and Schreiber, Falk},
  note={Article Number: 1282859}
}
kops.citation.iso690NIARAKIS, Anna, Marek OSTASZEWSKI, Alexander MAZEIN, Inna KUPERSTEIN, Martina KUTMON, Marc E. GILLESPIE, Akira FUNAHASHI, Michael AICHEM, Karsten KLEIN, Falk SCHREIBER, 2024. Drug-Target identification in COVID-19 disease mechanisms using computational systems biology approaches. In: Frontiers in Immunology. Frontiers. 2024, 14, 1282859. eISSN 1664-3224. Verfügbar unter: doi: 10.3389/fimmu.2023.1282859deu
kops.citation.iso690NIARAKIS, Anna, Marek OSTASZEWSKI, Alexander MAZEIN, Inna KUPERSTEIN, Martina KUTMON, Marc E. GILLESPIE, Akira FUNAHASHI, Michael AICHEM, Karsten KLEIN, Falk SCHREIBER, 2024. Drug-Target identification in COVID-19 disease mechanisms using computational systems biology approaches. In: Frontiers in Immunology. Frontiers. 2024, 14, 1282859. eISSN 1664-3224. Available under: doi: 10.3389/fimmu.2023.1282859eng
kops.citation.rdf
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/69067">
    <dc:contributor>Klein, Karsten</dc:contributor>
    <dc:contributor>Aichem, Michael</dc:contributor>
    <dc:creator>Niarakis, Anna</dc:creator>
    <dc:contributor>Gillespie, Marc E.</dc:contributor>
    <dc:creator>Ostaszewski, Marek</dc:creator>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2024-01-16T11:33:16Z</dc:date>
    <dc:contributor>Kutmon, Martina</dc:contributor>
    <dc:creator>Mazein, Alexander</dc:creator>
    <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/69067/1/Niarakis_2-5q540734qht31.pdf"/>
    <dc:contributor>Mazein, Alexander</dc:contributor>
    <dc:creator>Kuperstein, Inna</dc:creator>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/43615"/>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/36"/>
    <dc:creator>Schreiber, Falk</dc:creator>
    <dc:creator>Aichem, Michael</dc:creator>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dc:contributor>Ostaszewski, Marek</dc:contributor>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dc:contributor>Kuperstein, Inna</dc:contributor>
    <dc:creator>Kutmon, Martina</dc:creator>
    <dc:creator>Funahashi, Akira</dc:creator>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/43615"/>
    <dcterms:title>Drug-Target identification in COVID-19 disease mechanisms using computational systems biology approaches</dcterms:title>
    <dcterms:abstract>The COVID-19 Disease Map project is a large-scale community effort uniting 277 scientists from 130 Institutions around the globe. We use high-quality, mechanistic content describing SARS-CoV-2-host interactions and develop interoperable bioinformatic pipelines for novel target identification and drug repurposing. Extensive community work allowed an impressive step forward in building interfaces between Systems Biology tools and platforms.Our framework can link biomolecules from omics data analysis and computational modelling to dysregulated pathways in a cell-, tissue-or patient-specific manner. Drug repurposing using text mining and AI-assisted analysis identified potential drugs, chemicals and microRNAs that could target the identified key factors. Results revealed drugs already tested for anti-COVID-19 efficacy, providing a mechanistic context for their mode of action, and drugs already in clinical trials for treating other diseases, never tested against COVID-19. The key advance is that the proposed framework is versatile and expandable, offering a significant upgrade in the arsenal for virus-host interactions and other complex pathologies.</dcterms:abstract>
    <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/69067/1/Niarakis_2-5q540734qht31.pdf"/>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/69067"/>
    <dcterms:issued>2024-02-13</dcterms:issued>
    <dc:creator>Klein, Karsten</dc:creator>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2024-01-16T11:33:16Z</dcterms:available>
    <dc:contributor>Niarakis, Anna</dc:contributor>
    <dc:language>eng</dc:language>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/36"/>
    <dc:contributor>Schreiber, Falk</dc:contributor>
    <dc:creator>Gillespie, Marc E.</dc:creator>
    <dc:contributor>Funahashi, Akira</dc:contributor>
  </rdf:Description>
</rdf:RDF>
kops.description.openAccessopenaccessgold
kops.flag.etalAuthortrue
kops.flag.isPeerReviewedtrue
kops.flag.knbibliographytrue
kops.identifier.nbnurn:nbn:de:bsz:352-2-5q540734qht31
kops.sourcefieldFrontiers in Immunology. Frontiers. 2024, <b>14</b>, 1282859. eISSN 1664-3224. Verfügbar unter: doi: 10.3389/fimmu.2023.1282859deu
kops.sourcefield.plainFrontiers in Immunology. Frontiers. 2024, 14, 1282859. eISSN 1664-3224. Verfügbar unter: doi: 10.3389/fimmu.2023.1282859deu
kops.sourcefield.plainFrontiers in Immunology. Frontiers. 2024, 14, 1282859. eISSN 1664-3224. Available under: doi: 10.3389/fimmu.2023.1282859eng
relation.isAuthorOfPublication549e9182-c528-4817-81d8-00677d09a6a5
relation.isAuthorOfPublication783856d3-db6f-4abb-8969-9efd393896c7
relation.isAuthorOfPublication4a62a6c5-bf37-4efa-a633-4229ff88ed2e
relation.isAuthorOfPublication.latestForDiscovery549e9182-c528-4817-81d8-00677d09a6a5
source.bibliographicInfo.articleNumber1282859
source.bibliographicInfo.volume14
source.identifier.eissn1664-3224
source.periodicalTitleFrontiers in Immunology
source.publisherFrontiers

Dateien

Originalbündel

Gerade angezeigt 1 - 1 von 1
Vorschaubild nicht verfügbar
Name:
Niarakis_2-5q540734qht31.pdf
Größe:
5.98 MB
Format:
Adobe Portable Document Format
Niarakis_2-5q540734qht31.pdf
Niarakis_2-5q540734qht31.pdfGröße: 5.98 MBDownloads: 67